Benefits of pain relief on fatigue, function, and quality of life when joint inflammation is controlled in patients with RA
Prif Awduron: | Van De Laar, M, Pope, J, Lee, Y, Fautrel, B, Ikeda, K, Quebe, A, Zhang, X, Gaich, C, De Leonardis, F, Lisse, J, Workman, J, Taylor, P |
---|---|
Fformat: | Conference item |
Cyhoeddwyd: |
BMJ Publishing Group
2019
|
Eitemau Tebyg
-
Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
gan: Fautrel, B, et al.
Cyhoeddwyd: (2019) -
Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
gan: Taylor, P, et al.
Cyhoeddwyd: (2019) -
Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
gan: Fautrel, B, et al.
Cyhoeddwyd: (2017) -
Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
gan: Taylor, P, et al.
Cyhoeddwyd: (2019) -
Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
gan: Fautrel, B, et al.
Cyhoeddwyd: (2018)